Combination therapeutics for the world's toughest diseases
Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.
Founder
David has over 13 years of experience as a systems neuroscientist and biologist. His interest in systems biology led him to earn a PhD in Neuroscience at New York University and complete postdoctoral research at Harvard. During this time, he published more than 15 scientific articles and uncovered a link between oscillations in brain activity and glucose metabolism in the body (Tingley et al., Nature 2020).
Founder
Tom has over 15 years of industry experience leading teams and engineering technologies in aerospace, brain machine interfacing, synthetic biology and drug discovery/development. At Neuralink he built and co-led a group that developed a next-generation neural interface. At Loyal he built and led multiple teams as VP of Engineering, Computational Biology and Drug Development.
